Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5004 drug interaction study with itraconazole and oral contraceptives
NCT06942936Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of elecoglipron (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time zero to infinity at Day 10, Area under concentration-curve from time 0 to the last quantifiable concentration at Day 10 and 5 more. Started May 2025; status: completed.
02
Drugs
elecoglipron
Beyond the preview
Go deeper on NCT06942936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942936.